ABSTRACT
Objective: To study the lignans in the leaves of Magnolia denudata. Methods: The constituents were separated and purified by silica gel, Sephadex LH-20 and semi-preparative HPLC. The structures were elucidated on the basis of spectroscopic data analysis. All compounds were evaluated for their inhibitory activity against LPS-activated NO production in RAW 264.7 cell model in vitro. Results: Two tetrahydrofuran-type lignans and three dihydrobenzofuran-type lignans were isolated from 95% ethanol extract of M. denudate. Their structures were identified as (7S,7'R,8S,8'S)-3,4,5-trimethoxy-3',4'-methylenedioxy-7,7'-epoxylignan (1), veraguensin (2), liliflol A (3), liliflol B (4) and 5-methoxyliliflol B (5). Conclusion: Compound 1 is a new compound and named as magnodatin A. Compound 5 is a new natural product. The 13C-NMR spectroscopic data of compounds 3-5 are reported for the first time. Compound 5 exhibited weak inhibitory effect on NO production in LPS-induced macrophages with a inhibiton rate of 48.7% at 50 μmol/L.
ABSTRACT
Objective To study the chemical constituents from the leaves of Magnolia delavayi. Methods The chemical constituents were isolated and purified by column chromatography on silica gel, Sephadex LH-20, MCI, and HPLC. Their structures were identified based on spectroscopic data. Results Fourteen compounds were isolated from 95% ethanol aqueous extract of M. delavayi and the structures were identified as (2E)-3,7,11-trimethyl-2,10-dodecadien-l,6,7-triol (1), (2E,6E)-3,7,11-trimethyl-2,6-dodecadien-l,10,11- triol (2), loliolide (3), pinoresinol (4), syringaresinol (5), medioresinol (6), eudesmin (7), phillygenin (8), coniferaldehyde (9), 3,4,5-trimethoxycinnamyl alcohol (10), indole-3-carboxaldehyde (11), indole-3-ethanol (12), 3,4-dimethoxy-benzoic acid (13), and 3,4-dimethoxyphenol (14). Conclusion All compounds are isolated from this plant for the first time. In addition, the 1H- and 13C-NMR spectroscopic data are reported for the first time in the current study.
ABSTRACT
Objective@#To study the osteogenic potential of recombinant human bone morphogenetic protein 2 (rhBMP-2) combined with Bio-oss bone substitute in the implant restoration of bone defects in the anterior esthetic region. @*Methods@# Twelve patients who underwent the immediate placement of 20 implants with a bone augmentation procedure using rhBMP-2 and Bio-oss were included in this study. Changes in the height and thickness of the buccal bone over 6 months were measured, and the soft tissue was evaluated using the pink esthetic score (PES) after crown placement. @*Results@# All 20 implants were successfully osseointegrated, and the average increase in bone height was 1.9 mm; different degrees of bone height growth were observed for 17 (85%) implants sites. In one case, there was a severe bone fracture on the buccal side before the operation, resulting in bone plate resorption and decreased alveolar bone height. The bone height did not change significantly in 2 cases. The thickness of the buccal bone plate for all implants was greater than 1 mm. The average thickness was 1.9 mm, and the average PES was 9.8 points. @*Conclusion@# rhBMP-2 combined with Bio-oss bone substitute has a preferable effect on the restoration of bone defects in the anterior esthetic area, and can achieve good aesthetic effect.
ABSTRACT
AIM To study the chemical constituents from the twigs and leaves of Cryptomeria fortunei Hooibrenk ex Otto et Dietr.METHODS The ethyl acetate fraction of 95％ ethanol extract from C.fortunei was isolated and purified by silica,MCI,and Sephadex LH-20 column,then the structures of obtained compounds were identified by physicochemical properties and spectral data.RESULTS Eleven compounds were isolated and identified as isopimaric acid (1),sandaracopimaric acid (2),acetylisocupressic acid (3),imbricataloic acid (4),isocupressic acid (5),pinifolic acid (6),13-epicupressic acid (7),19-acetylagathadiol (8),agatadiol (9),phytol (10),elemol (11).CONCLUSION Compounds 1-10 are identified as diterpenoids and compound 11 is identified as sesquiterpenoid;Compounds 2,3,6-11 are obtained from this plant for the first time.
ABSTRACT
Objective:To compare clinicopathologic parameters of uncommon mutations of epidermal growth factor receptor (EGFR) and preliminary therapeutic effects of EGFR-TKI treatment in patients with non-small cell lung cancer. Methods:We collected clinico-pathological data from 29 patients with non-small cell lung cancer who carry uncommon mutations of EGFR, which were pathological-ly confirmed in the Tumor Hospital Affiliated to Xinjiang Medical University, from January 2012 to April 2016. Then we analyzed the re-lationship between the clinicopathologic characteristics of uncommon mutations and therapeutic effects of EGFR-TKIs. Results:Among the 29 cases of patients with uncommon mutations, the most common distant metastasis organs were ipsilateral/contralateral lung tissue, bone, brain, liver, and adrenal gland;the most common metastatic lymph nodes were hilar lymph node, supraclavicular/subclavian lymph node, neck-root lymph node, and mediastinal lymph node. In seldom mutations, 16 cases of single mutation were found:5 cases of L861Q, 5 cases of G719X, 4 cases of 20ins, and 2 cases of S768I. By contrast, 11 cases of double mutations were found:4 cases of S768I and 20ins, 1 case of double mutation of L858R and S768I, 1 case of double mutation of 19Del and T790M, 2 cases of double mutations of L861Q and G719X, 1 case of 19Del and S768I, 1 case of 20ins and G719X, and 1 case of T790M and G719X. Moreover, 2 cases of triple mutation were found:1 case of L858R, L861Q, and G719X;1 case of S768I, 20ins, and G719X. The objective response rate (ORR) of the first-line EGFR-TKI therapy was 43.75%, the disease control rate (DCR) was 50%, and the median progression-free survival (mPFS) was 5.5 months. Furthermore, the ORR of the second-line EGFR-TKI therapy was 28.57%, the DCR was 42.85%, and the mPFS was 4 months. Moreover, the ORR of the third-line EGFR-TKI therapy was 33.33%, the DCR was 50.00%, and the mPFS was 2.67 months. Conclusion:Great individual differences were found on EGFR uncommon mutations for effective rate and sur-vival time of EGFR-TKI treatment;in general, ORR and mPFS of EGFR seldom mutations were lower than classical mutations and partly higher than wild types. The first-line therapeutic effects of EGFR-TKI therapy was slightly better than the second-line or third-line thera-peutic effects;however, no significant statistical difference was observed .
ABSTRACT
BACKGROUND & OBJECTIVES: The fruits of Vitex rotundifolia L. are used as a traditional medicine in China. Dried fruits of V. rotundifolia (rich in essential oils) have been known to show strong estrogenic activity. Therefore, we investigated volatile components in the essential oil isolated from the fruits of V. rotundifolia and its estrogen-like biological activity in human breast adenocarcinoma cells. METHODS: Essential oil was extracted by SFE (supercritical fluid extraction) and its chemical composition was analysed by gas chromatography-mass spectrometry (GC-MS). The estrogenic activity of essential oil was evaluated in the MCF-7 cells by proliferation assay. RESULTS: The chemical composition of 40 compounds was determined and this represented 84.1 per cent of the total oil which was characterized by a high content of unsaturated fatty acids (54.84% of total oil). The oil contained mainly linoleic acid (47.46%), palmitic acid (5.18%), untriacontane (2.28%), bicetyl (2.61%) and stearic acid (2.2%). The essential oil strongly stimulated the proliferation of MCF-7 cells, and this effect was significantly inhibited by the specific estrogen receptor antagonist ICI 182,780. INTERPRETATION & CONCLUSION: Our results showed estrogen-like biological activity of the essential oil of the fruits from V. rotundifolia, and in future has a potential medical application.